Enhanced oral bioavailability of breviscapine after encapsulation in a liposomal formulation.
This report firstly describes the pharmacokinetic study of liposomal breviscapine (LB) after oral administration in rats. The mean Cmax and AUC(0-->t) of LB were 3.3 and 3.1-fold higher than those of breviscapine solution (BS). The oral absorption of breviscapine was significantly increased after encapsulation in the liposomal formulation.
Zhong
H J
HJ
Department of Pharmaceutical Science, School of Pharmacy, Shenyang Pharmaceutical University, Liaoning, PR China. effzhj@sina.com
Deng
Y J
YJ
Yang
B H
BH
Li
C L
CL
Du
S
S
D000818:Animals; D000925:Anticoagulants / Q000008:administration & dosage / Q000493:pharmacokinetics*; D019540:Area Under Curve; D001682:Biological Availability; D002626:Chemistry, Pharmaceutical; D002851:Chromatography, High Pressure Liquid; D004337:Drug Carriers; D004339:Drug Compounding; D005260:Female; D005419:Flavonoids / Q000008:administration & dosage / Q000493:pharmacokinetics*; D008081:Liposomes; D008297:Male; D051381:Rats; D017208:Rats, Wistar; D015203:Reproducibility of Results; D013056:Spectrophotometry, Ultraviolet
D000925:Anticoagulants; D004337:Drug Carriers; D005419:Flavonoids; D008081:Liposomes; C061097:breviscapine